Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIPEP-MUS
- Development stage
- Preclinical
- Lead developer
- Nano Intelligent Biomedical Engineering
- Modality
- Peptides
01
Overview
NIPEP-MUS is a peptide-based therapeutic candidate being developed by Nano Intelligent Biomedical Engineering Corporation (NIBEC) for the treatment of sarcopenia, an age-related condition characterized by the progressive loss of skeletal muscle mass and strength. Developed using NIBEC's proprietary peptide discovery platform, NIPEP-MUS is designed to act as a regenerative agent to restore muscle mass and function. The candidate is currently in the preclinical stage of development, where it is being evaluated for its efficacy in promoting muscle tissue repair and preventing atrophy. It is distinct from NIBEC's other sarcopenia candidate, NP-401, which specifically targets Klotho signaling.
Beyond the preview
Go deeper on NIPEP-MUS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIPEP-MUS.